ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects

Lin, Xiao-Min; Shi, Xiao-Xiao; Xiong, Le; Nie, Jun-Hua; Ye, Hai-Shan; Du, Jin-Zi; Liu, Jia*dalian med univ
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES2021-10DOI: 10.3390/ijms221910622
6被引8阅读
引用收藏
分享

摘要

Glioblastoma multiforme (GBM) is the most common lethal primary brain malignancy without reliable therapeutic drugs. IL-13R alpha 2 is frequently expressed in GBMs as a molecular marker. Resveratrol (Res) effectively inhibits GBM cell growth but has not been applied in vivo because of its low brain bioavailability when administered systemically. A sustained-release and GBM-targeting resveratrol form may overcome this therapeutic dilemma. To achieve this goal, encapsulated Res 30 +/- 4.8 nm IL-13R alpha 2-targeting nanoparticles (Pep-PP@Res) were constructed. Ultraviolet spectrophotometry revealed prolonged Res release (about 25%) from Pep-PP@Res in 48 h and fluorescent confocal microscopy showed the prolonged intracellular Res retention time of Pep-PP@Res (>24 h) in comparison with that of free Res (<4 h) and PP@Res (<4 h). MTT and EdU cell proliferation assays showed stronger suppressive effects of Pep-PP@Res on rat C6 GBM cells than that of PP@Res (p = 0.024) and Res (p = 0.009) when used twice for 4 h/day. Pep-PP@Res had little toxic effect on normal rat brain cells. The in vivo anti-glioblastoma effects of Res can be distinctly improved in the form of Pep-PP@Res nanoparticles via activating JNK signaling, upregulating proapoptosis gene expression and, finally, resulting in extensive apoptosis. Pep-PP@Res with sustained release and GBM-targeting properties would be suitable for in vivo management of GBMs.

学科与关键词

关键词
glioblastomaresveratrolIL-13R alpha 2Pep-PP@ResJNK signaling
相关
加载中…
  • Polyhedral Oligomeric Silsesquioxane-Based Nanoparticles for Efficient Chemotherapy of Glioblastoma
    Zhong, Xiangyang; Wei, Gang; Liu, Boyang; Wang, Chenyang; Wang, Juan; Lu, Yong*; Cui, Wenguo*; Guo, Hongbo*Small, 2023, 19(18).被引 3
  • LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy
    Zhang, Yufei; Cheng, Qian; Xue, Yuhao; Yao, Kai; Syeda, Madiha Zahra; Xu, Jian; Wu, Jianheng; Wang, Zhenjie*; Tang, Longguang*; Mu, Qingchun*Nano Research, 2023, 16(7): 9743-9751.被引 2
  • Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma
    Forrest M Kievit; Kui Wang; Tatsuya Ozawa; Aria W Tarudji; John R Silber; Eric C Holland; Richard G Ellenbogen; Miqin ZhangNanomedicine: Nanotechnology, Biology, and Medicine , 2017, 13(7): 2131-2139.
查看全部 →

发表信息

论文状态
公开发表
期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
发表日期
2021-10
卷期
第 22 卷, 第 19 期
页码
10622
DOI
10.3390/ijms221910622
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81272786, 81450016]; Basic Scientific Research Fund for Natural Science Subjects from South China University of Technology

作者

  • L

    Lin, Xiao-Min (第一作者)

  • S

    Shi, Xiao-Xiao

查看全部 7 位作者收起作者
  • X

    Xiong, Le

  • N

    Nie, Jun-Hua

  • Y

    Ye, Hai-Shan

  • D

    Du, Jin-Zi

  • L

    Liu, Jia (通讯)

    dalian med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417